Sign in
WithdrawnEarly phase 1

Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa

Key facts

Who runs it
University of North Carolina, Chapel Hill
Where
Chapel Hill, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Early phase 1
Started
1 Apr 2023
Ended
Sept 2024
Type of study
Interventional
Treatments tested
  • Fecal Microbiota Transplantation (FMT)
Record updated
30 January 2023
Why it stopped
Withdrawn due to covid-19 protocols on inpatient eating disorders unit.

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (32)Hide the full registry criteria

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Female aged 18-45
  • Diagnosed with SE-AN, defined here as having suffered from AN for five or more years and having participated in two or more inpatient or residential treatment programs followed by weight relapse
  • Sufficiently medically stable to receive FMT (serum electrolytes within normal limits, normal EKG)
  • Willing to adhere to the FMT dosing regimen
  • For females of reproductive potential, in sexual relationships with men, must use an acceptable method of contraception from 30 days prior to enrollment until 4 weeks after completing study treatment.* Participants must also be willing to be subjected to periodic pregnancy tests
  • Agreement to adhere to Lifestyle Considerations throughout study duration
  • Adequate insurance to cover inpatient stay; Lifestyle Considerations: During this study, participants are asked to:; Participate in standard inpatient treatment at UNC-Chapel Hill's CEED; Remain nil per os (npo) on the morning of each dosing session and for two hours after receiving FMT, on four individual instances of FMT administration; Abstain from sexual activity or use a condom or other form of highly effective birth control during the 30-day active stage of the clinical trial; Inform the research team as soon as possible if they become pregnant during the eight-week and six-month follow-up periods; If a trial participant has begun a course of one of this trial's prohibited medications during the eight-week or six-month follow-up periods, participants will be asked only to report the name of the medication, dose, and duration of treatment

Who cannot take part

  • Previous FMT or microbiome-based products at any time excluding this study
  • Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to start of study
  • Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy
  • Treatment with another investigational drug within the past month
  • Alcohol or drug dependence either at time of the study or within the last year
  • Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrollment. This does not include appendectomy or cholecystectomy
  • Solid organ transplant recipients less than or equal to 90 days posttransplant or on active treatment for rejection
  • Patients with allergies to ingredients Generally Recognized As Safe (GRAS)
  • Patients with a history of severe anaphylactic or anaphylactoid food allergy
  • Febrile illness within past month
  • Active gastrointestinal infection at time of enrollment
  • Any gastrointestinal or potentially intestinal microbiota-related conditions, including: Severe gastroparesis (e.g., gastric pacemaker) and any history of gastrointestinal illness (including but not limited to inflammatory bowel disease, irritable bowel syndrome, celiac disease, any gastrointestinal cancer, etc.)
  • Type 1 or 2 diabetes mellitus
  • History of total colectomy or bariatric surgery
  • If at risk for CMV/EBV associated disease (at investigator's discretion, e.g. immunocompromised), negative IgG testing for cytomegalovirus (CMV) or Epstein-Barr Virus (EBV)
  • A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study
  • Male or outside of the 18-45 range
  • Requires continued antibiotic use or anticipates antibiotic use in the upcoming 4 weeks
  • Pregnancy or lactation
  • Known or suspected toxic megacolon and/or known small bowel ileus
  • Patients who are immunocompromised
  • Unable or unwilling to comply with protocol requirements
  • Expected life expectancy < 6 months

Where in United States

  • UNC- Chapel HillChapel Hill, United States

About the trial

What the trial wants to find out

This is an open-label pilot study designed to explore the safety, feasibility, tolerability, and acceptability of fecal microbiota transplantation (FMT) in the treatment of severe and enduring anorexia nervosa (SE-AN).

The group in the trial

  • FMT for SE-ANTreatment being tested

    Inpatients at the UNC-Chapel Hill Center of Excellence for Eating Disorders (CEED) and will receive weekly fecal microbiota transplantations for four weeks. This will be in addition to standard care at CEED.

    Treatment: Fecal Microbiota Transplantation (FMT)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Severe and Enduring Anorexia Nervosa (SE-AN)
Record updated
30 January 2023